Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines

Anticancer Research

Volumn 33, Issue 1, 2013, Pages 123-132

  Gong, Yongmei ^a   Gallis, Byron M ^a   Goodlett, David R ^a   Yang, Yi ^b   Lu, Hailing ^b   Lacoste, Eric ^a,d   Lai, Henry ^c   Sasaki, Tomikazu ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c University of Washington   (United States)

^d SANOFI   (France)

Author keywords

Artemisinin; Breast cancer; C Myc; Cyclin D1; DV145; HER2; MCF7 cells; Survivin; Transferrin

Indexed keywords

ARTEMISININ; BETA CATENIN; CYCLIN D1; DIMER; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MYC PROTEIN; SURVIVIN; TRANSFERRIN;

APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); DOWN REGULATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN STRUCTURE; WNT SIGNALING PATHWAY;

APOPTOSIS; ARTEMISININS; BETA CATENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; PROSTATIC NEOPLASMS; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; TRANSFERRIN; WNT SIGNALING PATHWAY;

EID: 84873023631     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP and White NJ: Artesunate versus quinine in the treatment of severe falciparum malaria in african children (aquamat): An open-label, randomised trial. Lancet 376: 1647-1657, 2010.
2. White NJ: Qinghaosu (artemisinin): The price of success. Science, pp 330-334, 2008.
3. Maude RJ, Plewes K, Faiz MA, Hanson J, Charunwatthana P, Lee SJ, Tarning J, Yunus EB, Hoque MG, Hasan MU, Hossain A, Lindegardh N, J. DNP, White NJ and Dondorp AM: Does artesunate prolong the electrocardiograph qt interval in patients with severe malaria? Am J Trop Med Hyg 80: 126-132, 2009.
4. Taylor WR and White NJ: Antimalarial drug toxicity: A review. Drug Safety 27: 25-61, 2004.
5. Singh NP and Panwar VK: Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther 5: 391-394, 2006.
6. Singh NP and Verma BV: Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch Oncol 10: 279-280, 2002.
7. Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk J-O, Baur A and Schuler G: Artesunate in the treatment of metastatic uveal melanoma - first experiences. Oncol Rep 14: 1599-1603, 2005.
8. Karin M and Mintz B: Receptor-mediated endocytosis of transferrin in developmentally totipotent mouse teratocarcinoma stem cells. J Biol Chem 256: 3245-3252, 1981.
9. Das-Gupta A, Patil J and Shah V: Transferrin receptor expression by blast cells in acute lymphoblastic leukemia correlates with white cell count and immunophenotype. Indian J Med Res 104: 226-233, 1996.
10. May WS and Cuatrecasas P: Transferrin receptor: Its biological significance. J Membrane Biol 88: 205-215, 1985.
11. Raaf HN, Jacobsen DW, Savon S and Green R: Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast. Am J Clin Pathol 99: 232-237, 1993.
12. Reizenstein P: Iron, free radicals and cancer. Med Oncol Tumor Pharmacother 8: 229-233, 1991.
13. Lai H, Sasaki T, Singh NP and Massey A: Effects of artemisinintagged holotransferrin on cancer cells. Life Sci 76: 1267-1279, 2005.
14. Oh S, Kim B-J, Singh NP, Lai H and Sasaki T: Synthesis and anticancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett 274: 33-39, 2009.
15. Nakase I, Gallis B, Takatani-Nakase T, Oh S, Lacoste E, Singh NP, Goodlett DR, Tanaka S, Futaki S, Lai H and Sasaki T: Transferrin receptor-dependent cytotoxicity of artemisinintransferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett 274: 290-298, 2009.
16. Posner GH, Paik I-H, Sur S, McRiner AJ, Borstnik K, Xie S and Shapiro TA: Orally active, antimalarial, anticancer, artemisininderived trioxane dimers with high stability and efficacy. J Med Chem 46: 1060-1065, 2003.
17. Paik I-H, Xie S, Shapiro TA, Labonte T, Narducci SAA, Baege AC and Posner GH: Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity. J Med Chem 49: 2731-2734, 2006.
18. Nam W, Tak J, Ryu J-K, Jung M, Yook J-I, Kim H-J and Cha I-H: Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. Head Neck 29: 335-340, 2007.
19. Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul W, Slade D, Galal AM and Newton DL: Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int J Cancer 125: 1266-1275, 2009.
20. Rosenthal AS, Chen X, Liu JO, West DC, Hergenrother PJ, Shapiro TA and Posner GH: Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells. J Med Chem 52: 1198-1203, 2009.
21. Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, Goodlett DR, Vessella RL and Sasaki T: Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs 21: 423-432, 2010.
22. Posner GH, McRiner AJ, Paik I-H, Sur S, Borstnik K, Xie S, Shapiro TA, Alagbala A and Foster B: Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. J Med Chem 47: 1299-1301, 2004.
23. Low ICC, Kang J and Pervaiz S: Bcl-2: A prime regulator of mitochondrial redox metabolism in cancer cells. Antioxid Rdox Signal 15: 2975-87, 2011.
24. Mu D, Chen W, Yu B, Zhang C, Zhang Y and Qi H: Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer spc-a-1 cells. Methods Find Exp Clin Pharmacol 29: 33-38, 2007.
25. Mityaev MV, Kopantzev EP, Buzdin AA, Vinogradova TV and Sverdlov ED: Functional significance of a putative sp1 transcription factor binding site in the survivin gene promoter. Biochemistry (Moscow) 73: 1183-1191, 2008.
26. Baryawno N, Sveinbjornsson B, Eksborg S, Chen C-S, Kogner P and Johnsen JI: Small-molecule inhibitors of phosphatidylinositol 3-kinase/akt signaling inhibit wnt/β-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res 70: 266-276, 2010.
27. Guha M and Altieri DC: Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 8: 2708-2710, 2009.
28. Huang L, Shitashige M, Satow R, Honda K, Ono M, Yun J, Tomida A, Tsuruo T, Hirohashi S and Yamada T: Functional interaction of DNA topoisomerase iiα with the β-catenin and tcell factor-4 complex. Gastroenterology 133: 1569-1578, 2007.
29. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W and Huelsken J: Cutaneous cancer stem cell maintenance is dependent on -catenin signalling. Nature 452: 650-654, 2008.
30. Murphy CG and Modi S: Her2 breast cancer therapies: A review. Biologics: Targets & Therapy 3: 289-301, 2009.
31. Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S and Spector NL: Regulation of survivin by erbb2 signaling: Therapeutic implications for erbb2-overexpressing breast cancers. Cancer Res 66: 1640-1647, 2006.
32. Lai H, Nakase I, Lacoste E, Singh NP and Sasaki T: Artemisinin- transferrin conjugate retards growth of breast cancer in the rat. Anticancer Res 29: 3807-3810, 2009.
33. Papanikolaou V, Iliopoulos D, Dimou I, Dubos S, Kappas C, Kitsiou-Tzeli S and Tsezou A: Survivin regulation by her2 through nf-κb and c-myc in irradiated breast cancer cells. J Cell Mol Med 15: 1542-1550, 2011.
34. Cheng Y, Zak O, Aisen P, Harrison SC and Waltz T: Structure of the human transferrin receptor-transferrin complex. Cell 116: 565-576, 2004.
35. Lim CJ and Shen WC: Transferrin-oligomers as potential carriers in anticancer drug delivery. Pharmaceutical Res 21: 1985-1992, 2004.
36. Pang Z, Gao H, Yu Y, Guo L, Chen J, Pan S, Ren J, Wen Z and Jiang X: Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin. Bioconjug Chem 22: 1171-1180, 2011.
37. Yamamoto H, Ngan CY and Monden M: Cancer cells survive with survivin. Cancer Sci 99: 1709-1714, 2008.
38. Li L-N, Zhang H-D, Yuan S-J, Tian Z-Y, Wang L and Sun Z-X: Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive wnt/β-catenin pathway. Int J Cancer 121: 1360-1365, 2007.
39. Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K, Nakano T, Miura M and Shiraki K: Survivin initiates procaspase 3/p21 complex formation as a result of interaction with cdk4 to resist fas-mediated cell death. Oncogene 19: 1346-1353, 2000.
40. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A and Antonia B: Phase i and pharmacokinetic study of ym155, a small-molecule inhibitor of survivin. J Clin Oncol 26: 5198-5203, 2008.
41. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M and Sasamata M: Ym155, a novel small-molecule survivin suppressant, induces regression of established human hormonerefractory prostate tumor xenografts. Cancer Res 67: 8014-8021, 2007.
42. Masamha CP and Benbrook DM: Cyclin d1 degradation is sufficient to induce g1 cell cycle arrest despite constitutive expression of cyclin e2 in ovarian cancer cells. Cancer Res 69: 6565-6572, 2009.
43. Shan J, Zhao W and Gu W: Suppression of cancer cell growth by promoting cyclin d1 degradation. Mol Cell 36: 469-476, 2009.
44. Ruggero D: The role of myc-induced protein synthesis in cancer. Cancer Res 69: 8839-8843, 2009.
45. Cole MD and Cowling VH: Transcription-independent functions of myc: Regulation of translation and DNA replication. Nature Rev Mol Cell Biol 9: 810-815, 2008.
46. Li L-N, Zhang H-D, Yuan S-J, Yang D-X, Wang L and Sun Z-X: Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and ecadherin. Eur J Pharmacol 588: 1-8, 2008.
47. Lai S-L, Chien AJ and Moon RT: Wnt/fz signaling and the cytoskeleton: Potential roles in tumorigenesis. Cell Res 19: 532-535, 2009.
48. Verras M and Sun Z: Roles and regulation of wnt signaling and β-catenin in prostate cancer. Cancer Lett 237: 22-32, 2006.
49. Citri A, Kochupurakkal BS and Yarden Y: The achilles heel of erbb-2/her2: Regulation by the hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3: 50-59, 2004.
50. Ryan BM, Konecny GE, Kahlert S, Wang H-J, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ and Duffy MJ: Survivin expression in breast cancer predicts clinical outcome and is associated with her2, vegf, urokinase plasminogen activator and pai-1. Ann Oncol 17: 597-604, 2006.
51. Deming SL, Nass SJ, Dickson RB and Trock BJ: C-MYC amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83: 1688-1695, 2000.
52. Firestone GL and Sundar SN: Anticancer activities of artemisinin and its bioactive derivatives. Expert Reviews in Molecular Medicine 11: e32, 2009.